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Abstract
AIM: To evaluate the clinical outcomes and prognostic 
factors after intravenous corticosteroids following oral 
corticosteroid failure in active ulcerative colitis patients.
METHODS: Consecutive patients with moderate to 
severe ulcerative colitis who had been treated with a 
course of intravenous corticosteroids after oral corti-
costeroid therapy failure between January 1996 and 
July 2010 were recruited at Severance Hospital, Seoul, 
South Korea. The disease activity was measured by the 
Mayo score, which consists of stool frequency, rectal 
bleeding, mucosal appearance at flexible sigmoidos-
copy, and Physician Global Assessment. We retrospec-
tively evaluated clinical outcomes at two weeks, one 
month, three months, and one year after the initiation 
of intravenous corticosteroid therapy. Two weeks out-
comes were classified as responders or non-responders. 
One month, three month and one year outcomes were 
classified into prolonged response, steroid dependency, 
and refractoriness.
RESULTS: Our study included a total of 67 eligible pa-
tients. At two weeks, 56 (83.6%) patients responded 
to intravenous corticosteroids. At one month, complete 
remission was documented in 18 (32.1%) patients 
and partial remission in 26 (46.4%). Eleven patients 
(19.7%) were refractory to the treatment. At three 
months and one year, we found 37 (67.3%) and 25 
(46.3%) patients in prolonged response, ten (18.2%) 
and 23 (42.6%) patients in corticosteroid dependency, 
8 (14.5%) and 6 (11.1%) patients with no response, 
respectively. Total 9 patients were underwent elective 
proctocolectomy within 1 year. The duration of oral cor-
ticosteroid therapy (> 14 d vs ≤ 14 d, P = 0.049) and 
lower hemoglobin level (≤ 11.0 mg/dL vs >11.0 mg/
dL, P  = 0.02) were found to be poor prognostic factors 
for response at two weeks. For one year outcome, uni-
variate analysis revealed that only a partial Mayo score 
(≥ 6 vs <6, P  = 0.057) was found to be associated 
with a poor response.
CONCLUSION: The duration of oral corticosteroid 
therapy and lower hemoglobin level were strongly as-
sociated with poor outcome.
© 2013 Baishideng. All rights reserved.
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INTRODUCTION
Ulcerative colitis (UC) is a chronic inflammatory disease 
of  the colon with unknown etiology and is characterized 
by a typical natural course with recurrent flares of  muco-
sal inflammation. About 15% of  patients with UC have 
been reported to have an overall chance of  acute exacer-
bation and require admission to hospital and treatment 
with systemic corticosteroids[1,2]. Systemic corticosteroids 
remain as the gold standard treatment of  acute moderate 
to severe UC. However, about 15%-57% of  UC patients 
remain steroid-dependent or refractory even after steroid 
treatment[3]. Before the mid-1990s, proctocolectomy was 
the only treatment in steroid-unresponsive UC patients. 
Recently, intensive drug therapies have been shown to 
be effective in reducing and delaying the need for colec-
tomy[4,5].
For UC patients who fail to improve with a maximal 
dosage of  5-aminosalicylic acids, oral steroid therapy 
should be considered. Moreover, for those who also do 
not respond to orally administered steroids, hospital ad-
mission is usually required for intensive intravenous treat-
ment[6,7]. However, to the best of  our knowledge, there 
has been no published study describing the clinical course 
of  patients with acute attack of  UC who were treated 
first with oral corticosteroids and subsequently with in-
travenous corticosteroids due to oral steroid failure. Be-
fore demonstrating the efficacy of  second line drugs, the 
response and the clinical outcomes of  intravenous cor-
ticosteroid therapy after oral administration need to be 
clarified. In addition, identification of  early predictors of  
intravenous corticosteroid responsiveness could facilitate 
appropriate patient selection and well-timed administra-
tion of  second line therapies in such UC patients. Clini-
cally, earlier detection of  response is important to help 
estimate risks, benefits, and duration of  treatment, as this 
will enable the use of  alternative drugs before complica-
tions of  long term use of  systemic corticosteroids can 
develop. However, data on predictive response factors of  
intravenous corticosteroids following oral corticosteroid 
therapy are lacking.
Here we sought to identify predictive clinical or bio-
logical factors associated with intravenous corticosteroid 
responsiveness in UC patients that initially did not re-
spond to oral corticosteroids, as well as two week, one 
month, three month, and one year clinical outcomes of  
such treated patients with acute attack of  UC.
MATERIALS AND METHODS
Patients
The clinical records of  patients with active UC who 
were treated with intravenous corticosteroids immedi-
ately after treatment failure of  oral corticosteroids at the 
Yonsei University College of  Medicine, Seoul, South 
Korea between January 1996 and July 2010 were retro-
spectively evaluated. The diagnosis of  ulcerative colitis 
was based on the accepted clinical, endoscopic, and his-
topathological criteria[8]. The criteria for eligibility were 
male or female patients with a diagnosis of  UC followed 
regularly for at least 1 year. The exclusion criteria were 
patients with a history of  corticosteroid therapy at other 
hospitals, corticosteroid use for diseases other than UC 
and a follow-up duration of  less than 1 year. All enrolled 
patients were initiated intravenous corticosteroid therapy 
after admission after failure of  oral steroid therapy which 
was done at outpatient clinic.
Intravenous corticosteroid therapy was initiated with 
intravenous administration of  100 mg of  hydrocortisone 
every eight hours. Intravenous corticosteroid therapy was 
continued for 1-2 wk, with the treatment duration de-
pending on the individual patient conditions, followed by 
gradual tapering of  corticosteroids. After clinical improve-
ment of  UC, the dose of  intravenous hydrocortisone was 
reduced to 200 mg daily. If  the patients had no clinical 
exacerbation of  UC, they were administered 30 mg/d 
of  oral corticosteroid therapy before discharge. Our oral 
corticosteroid tapering policy was to reduce prednisolone 
by 5 or 10 mg weekly for patients with improved clini-
cal symptoms but to sustain the current dose of  pred-
nisolone for one week for patients with lasting clinical 
symptoms[9,10]. All patients who were concomitantly taking 
sulfasalazine (2-4 g/d) or mesalamine (1.5-4 g/d) at the 
time of  flare up continued therapy. Patients who took 
immuomodulators at the time of  acute flare up also main-
tained their initial immuomodulator therapy while taking 
corticosteroids.
Our study is a retrospective study from a prospec-
tively collected database. The data are stored in a form 
of  Assess file as well as paper form. After then, the ques-
tionnaire including Mayo or partial Mayo scores including 
Physician Global Assessment (PGA) is updated every 
visit of  the patient to outpatient clinics.
The disease activity was measured by the Mayo score, 
which consists of  stool frequency, rectal bleeding, muco-
sal appearance at flexible sigmoidoscopy, and PGA[11,12]. 
Each component was scored 0 to 3 points, and the total 
score ranged from 0 to 12 points. However, a measure-
ment of  this score necessarily requires invasive flexible 
sigmoidoscopy, which limits repeated measurement. 
Therefore, most actual disease activity was measured 
on a nine-point partial Mayo score, which excluded the 
mucosal appearance at endoscopy[13]. At the initiation of  
oral corticosteroid therapy, demographic data including 
age, age at diagnosis, duration, gender, number of  acute 
attacks, extent of  disease, concomitant medications, du-
ration of  oral corticosteroid therapy, Mayo score, and 
partial Mayo score were collected. Partial Mayo score and 
laboratory parameters were also recorded at two weeks, 
one month, three months, and one year after the time 
of  initiation of  intravenous corticosteroid therapy. This 
study was approved by the institutional board of  Sever-
ance Hospital.
Definitions
Clinical outcome was measured at two weeks, one month, 
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three months, and one year after the initiation of  intra-
venous corticosteroids. The classification of  response to 
intravenous corticosteroid therapy was adopted from pre-
vious studies with minor modification[3,11,14,15]. Patients at 
two weeks were classified as responders or non-respond-
ers. Non-responder of  intravenous therapy after oral 
corticosteroid therapy was defined as persistent active 
disease despite administration of  intravenous corticoste-
roids over two weeks, death due to UC attack before day 
14, proctocolectomy before day 14, or secondary alterna-
tive drug use such as cyclosporine and infliximab before 
day 14. Proctocolecctomy was performed when the pa-
tient had intractable bloody diarrhea, a continued PGA 
score of  3, severe anemia, persistent abdominal pain, or 
severe malnutrition despite intensive medical treatment. 
One month outcomes were classified as complete remis-
sion, partial remission, or refractoriness. Complete re-
mission was defined as a stool frequency ≤ 2/d with no 
rectal bleeding, stool urgency, fever, or any other systemic 
symptoms, and a PGA score of  0. Partial remission was 
defined as stool frequency ≤ 4/d or ≤ 50% of  initial 
stool frequency with regression of  other clinical symp-
toms and a PGA score of  1 or 2. Refractoriness was de-
fined as persistent active status despite administration of  
prednisolone up to 30 mg/d or the equivalent dose over 
the period of  four weeks[14]. Three month outcomes were 
classified into prolonged response, steroid dependency, 
and refractoriness. Prolonged response was defined 
as sustained complete or partial remission during the 
planned dose reduction or after the completion of  corti-
costeroids[3]. Steroid dependency was defined as need for 
the same corticosteroid dose for more than two weeks 
despite clinical improvement, requiring an increased dose, 
or restarting corticosteroid therapy within two weeks be-
cause of  exacerbation of  symptoms[11,14]. Refractoriness 
was defined as no improvement of  clinical symptoms 
despite continued corticosteroid use. Similarly, outcomes 
at one year were subdivided into three groups. Prolonged 
response was characterized by two conditions: maintain-
ing complete or partial remission after discontinuation of  
corticosteroid therapy and requiring the same dose for 
more than two weeks or an increasing dose of  corticoste-
roids only in the first three months. Steroid dependency 
was defined as restart of  corticosteroid therapy due to 
recurrent flare-up of  UC after the first three months or 
being unable to reduce prednisolone to 10 mg/day within 
three months. Non-response was defined in the same way 
as for the intermediate outcomes.
Statistical analysis
Continuous variables were presented as the mean ± SD 
or median (range) and were compared using two-sample 
t tests. Categorical variables were compared by χ 2 tests 
or Fisher’s exact test. Logistic regression analysis was 
performed to identify predictive variables of  clinical out-
comes. P values less than 0.05 were considered statistical-
ly significant. All the statistical analyses were performed 
using the statistical software package SPSS 12.0 for Win-
dows (SPSS Inc., Chicago, IL).
RESULTS
Patient characteristics
A total of  67 patients, 39 men and 28 women, with active 
UC were included in this study (Table 1). The median age 
at diagnosis was 31 years (range: 11-78 years), and median 
disease duration at the time of  oral corticosteroid therapy 
was 24 mo (range: 0-132 mo). The median length of  oral 
corticosteroid use before intravenous therapy was 13 d 
(range: 3-50 d). Forty-one (61.2%) patients had extensive 
disease, and 32 (47.8%) had their first attack of  active 
UC.
Clinical outcomes after intravenous corticosteroid 
therapy
Clinical outcomes of  patients were organized in a flow 
chart (Figure 1). At two weeks after treatment, 56 (83.6%) 
patients responded to intravenous systemic corticoste-
roids. Seven of  the 11 non-responders underwent proc-
tocolectomy before day 14. Three patients were treated 
with an intravenous tumor necrosis factor-α blocker, and 
one patient was treated with intravenous cyclosporine. 
At one month after treatment, 18 (32.1%) patients were 
in complete remission, 26 (46.4%) in partial remission, 
and 12 (21.5%) had no response. Collectively, 21.5% of  
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Table 1  Baseline characteristics of patients with active 
ulcerative colitis receiving intravenous corticosteroids after 
oral corticosteroid therapy failure
Total patients (n  = 67)
Gender (male/female) 39/28 (58.2/41.8)
Age (yr) 35 (13-78)
Age at diagnosis (yr) 31 (11-78)
Disease duration (mo) 24 (0-132)
Disease extent
   Proctitis 5 (7.5)
   Left-sided colitis 21 (31.3)
   Extensive colitis 41 (61.2)
First attack of UC 32 (47.8)
Number of previous flares 2 (1-4)
Initial disease activity
   Full Mayo score 9 (5-10)
   Partial Mayo score 6 (3-7)
Initial prednisolone dose (mg)
   ≥ 30 and < 40 35 (52.2)
   ≥ 40 32 (47.8)
Duration of oral corticosteroid use (d) 13 (3-50)
Maintenance before flare up
   None/salicylates/azathioprine 6/47/14
Concomitant medications
   Salicylates 53
   Azathioprine 14
CRP (mg/dL)   10.9 (0.1-153.0)
ESR (mm/h)   40.0 (3.0-120.0)
Hemoglobin (mg/dL) 11.7 (6.4-16.5)
Albumin (mg/dL) 3.6 (2.3-5.0)
Data are expressed as absolute numbers (percentage) or median. UC: 
Ulcerative colitis; CRP: C-reactive protein; ESR: Erythrocyte sedimentation 
rate.
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that were found to be statistically significant by univariate 
analysis.
For two weeks outcomes, univariate analysis of  pre-
dictors for non-responders showed that disease duration 
(> 24 mo), duration of  oral corticosteroids use (> 14 
days), and lower hemoglobin level (≤ 11 mg/dL) were 
associated with poor prognosis. According to multivari-
ate analysis, the duration of  oral corticosteroids use (> 
14 d vs ≤ 14 d, P = 0.049) and lower hemoglobin level 
(≤ 11.0 mg/dL vs > 11.0 mg/dL, P = 0.02) remained 
predictive factors for non-responders (Table 2). No pre-
dictive factors for poor responders at one month or three 
months were identified (Tables 3 and 4). For one year 
outcome, univariate analysis revealed that only a partial 
Mayo score (≥ 6 vs < 6, P = 0.057) was found to be as-
sociated with a poor response (Table 5).
DISCUSSION
We analyzed the clinical outcomes and identified predic-
tive factors associated with corticosteroid responsiveness 
of  patients who had an acute attack of  UC and had been 
administered intravenous corticosteroids after a previ-
ous course of  systemic oral corticosteroid therapy. There 
have been many previous studies that have reported the 
predictors of  clinical response to systemic corticosteroid 
treatment in moderate to severe active UC patients[16-19]. 
However, there are few reports of  outcomes of  a conser-
vative approach of  intravenous steroid treatment in mod-
erate to severe active UC patients after oral corticosteroid 
therapy failure.
In our study, intravenous corticosteroid therapy fol-
lowing a failure after oral corticosteroid therapy was suc-
cessful at inducing response at two weeks of  treatment 
in 83.6% of  patients. This result implies that intravenous 
corticosteroids could be administered when a lack of  
response to oral corticosteroid therapy is shown. This 
patients showed treatment failure to systemic corticoste-
roid therapy, and the other 78.5% of  patients showed a 
partial or complete response to intravenous corticoste-
roid therapy. At three months, 37 patients had prolonged 
response, ten had steroid dependency, and seven showed 
no response. Of  the 11 patients who were refractory to 
corticosteroid therapy at one month, two were in partial 
remission, two were steroid-dependent, seven had per-
sistent refractoriness at three months, and one patient, a 
59-year-old man who underwent proctocolectomy, died 
of  pneumonia and sepsis. At one year, 25 of  the 67 pa-
tients (37.3%) were categorized with prolonged response, 
23 as steroid-dependent (34.3%), and six as non-respond-
ers (9.0%).
In our study, cytomegalovirus infection was detected 
in 5 patients. All were diagnosed by histologic examina-
tions and were treated with ganciclovir. Of  these, one 
patient underwent proctocolectomy within 14 d after the 
treatment. The rest of  them responded to ganciclovir 
treatment. Finally, three patients were in partial remission 
and one patient was steroid dependent at one year.
Predictive factors for favorable outcomes
We performed univariate and multivariate analyses to 
detect clinical or laboratory factors capable of  predict-
ing poor outcomes of  intravenous corticosteroid therapy 
after oral corticosteroid therapy failure. For the evalu-
ation of  intravenous corticosteroids at two weeks, we 
divided all patients into two groups: responders and non-
responders who experienced death, proctocolectomy, or 
secondary medical treatment before two weeks. Patients 
were also divided into good responders and poor re-
sponders at one month, three months, and at one year 
after the corticosteroids therapy: good responders were 
those who showed a prolonged response, and poor re-
sponders were steroid-dependent or non-responsive. 
Multivariate analysis was carried out using the factors 
N: 67
Responder 56 (83.6%)
Non responder 11 (16.4%)
7 colectomy
1 Ⅳ-cyclosporine
3 Ⅳ-remicade
2 wk
CR 18 (32.1%) PR 26 (46.4%) NR 12 (21.5%) 11: Refractoriness
1: Colectomy
1 mo
  Prolonged response   
37 (67.3%)
 Steroid dependency 10 
(18.2%)
NR 8 (14.5%)3 mo
Prolonged response
25 (46.3%)
Steroid dependency
23 (42.6%)
NR 6 (11.1%)1 yr
7: Refractoriness
1: Death
1 2
2 3
5
2 1
7
2 1
1 8 3 1
1 4
Figure 1  Clinical outcomes of patients with active ulcerative colitis treated with intravenous corticosteroids in oral corticosteroid refractory patients. CR: 
Complete remission; PR: Partial remission; NR: Non-response. 
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result was partly explained by previous pharmacokinetic 
studies, which demonstrated delayed prednisolone ab-
sorption after an oral dose in patients with acute colitis 
as compared to healthy controls and higher plasma levels 
after intravenous steroid administration[20,21]. In addition, 
intravenous steroid administration in the hospital ensures 
good treatment compliance. 
The rate of  failure of  intravenous corticosteroid therapy 
in moderate to severe UC attacks was quite high, account-
ing for 30%-40% in recent studies investigating Western 
populations[16-19,22,23]. Moreover, Meyers et al[24] showed a 
better clinical improvement of  intravenous corticotro-
phin therapy for acute UC in steroid-naïve patients than 
in patients who had already received steroid treatment. 
Considering that our enrolled patients were an oral corti-
costeroid failure group and approximately half  of  them 
were non steroid-naïve patients, our results at two weeks 
showed a much higher response rate to intravenous corti-
costeroid therapy compared with previous studies[16-19,22,23]. 
Moreover, In our study, 13.4% of  patients underwent 
proctocolectomy or experienced death within one year, 
while the incidence of  cumulative proctocolectomy was 
reported to be about one-fifth that of  exacerbation of  
UC[25-27]. This difference in the results of  steroid treat-
ment reaffirms the previous report that UC patients in 
the Korean population have a lower cumulative prob-
ability of  proctocolectomy compared to those in Western 
countries[28,29]. Taken together, these results suggest that 
Korean patients with UC might have a more favorable 
prognosis compared to Western counterparts. In order 
to investigate the clinical application of  our results in the 
treatment of  UC patients, further prospective studies are 
warranted.
One month after the initiation of  intravenous corti-
costeroid therapy, 78.5% of  patients (32.1% with com-
plete response and 46.4% with partial response) showed 
clinical improvement, whereas 42.6% were dependent 
on steroids at one year. It has been previously reported 
that 22% of  patients in a western study became steroid-
dependent[3]. Recently, Yoon et al[10] reported that a ste-
roid-naïve Korean UC patient showed a good response 
to steroid treatment, while 40% of  UC patients eventu-
ally became steroid-dependent or refractory. Our study 
showed that the responses to intravenous corticosteroids 
following a failure after oral corticosteroid treatment were 
similarly favorable in the short term period. However, 
more than half  of  patients eventually became steroid-
dependent or refractory in the long term.
Table 2  Comparison of clinical factors in immediate outcomes of the two groups of active ulcerative colitis patients receiving 
intravenous corticosteroids after oral corticosteroid therapy failure
Responders (n  = 56) Non-responders1 (n  = 11)  P -value Odds ratio (95%CI)
Univariate Multivariate
Gender (M/F)       32/24 (57.1/42.9)        7/4 (63.6/36.4) 0.690
Age (yr)      37 (13-78)   39 (29-50) 0.458
Disease duration (mo)
   ≤ 24    34 (60.7)   3 (27.3) 0.041   0.123   3.38 (0.72-15.88)
   > 24    22 (39.3)   8 (72.7)
First attack of UC    26 (46.4)   6 (54.5) 0.273
Disease extent 0.884
   Proctitis    4 (7.1) 1 (9.1)
   Left-sided colitis    17 (30.4)   4 (36.4)
   Extensive colitis    35 (62.5)   6 (54.5)
Disease activity
   Full Mayo score (< 9/≥ 9)       27/24 (52.9/47.1)        3/8 (27.3/72.7) 0.122
   Partial Mayo score (< 6/≥ 6) 14/42 (25/75)    1/10 (9.1/90.9) 0.227
Initial prednisolone dose (mg) 0.622
   ≥ 30 and < 40    29 (51.8)   6 (54.5)
   ≥ 40    27 (48.2)   5 (45.5)
Duration of oral corticosteroid use (d)
   ≤ 14    33 (58.9)   3 (27.3) 0.054   0.049     4.9 (1.01-23.81)
   > 14    23 (41.1)   8 (72.7)
Concomitant medications 0.809
   Salicylates    44 (78.6)   9 (81.8)
   Azathioprine    12 (21.4)   2 (18.2)
CRP (mg/dL)
   ≤ 8    37 (66.1) 11 (84.6) 0.303
   > 8    19 (33.9)   2 (15.4)
ESR (mm/h)      40 (3-120)   40 (12-83) 0.999
Hemoglobin (mg/dL)
   ≤ 11    18 (32.1)   8 (72.7) 0.012 0.02 0.16 (0.03-0.75)
   > 11    38 (67.9)   3 (27.3)
Albumin (mg/dL)     3.63 (2.3-5.0)   3.56 (2.8-4.8) 0.331
1Non-responder group included patients that had secondary alternative drug use, proctocolectomy and death before day 14. M/F: Male/female; UC: 
Ulcerative colitis; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate. 
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Reports evaluating predictive factors for poor clini-
cal outcomes have shown different and controversial 
results. Some found no predictive factors[15,24,30] while 
others showed several factors related to clinical out-
comes[16-19,22,23]. In our study, the UC duration, the dura-
tion of  oral corticosteroid use, and lower hemoglobin 
level were associated with failure of  steroid treatment 
on univariate analysis. Of  these variables, only duration 
of  oral corticosteroid therapy and lower hemoglobin 
level were found to be independently associated with 
failure of  corticosteroid therapy on multivariate analysis. 
Knowledge of  the clinical factors associated with non-
response to intravenous corticosteroid therapy after oral 
therapy may be useful in clinical decision-making. Our 
study was such an attempt to explain this situation. Our 
results showing the relationships between simple clinical 
factors, such as lower hemoglobin or duration of  oral 
steroid use, and intravenous treatment outcome might 
help in predicting poor responders. Lower hemoglobin 
level as a risk factor for poor response in our study is in 
accordance with an earlier reports, which reflects that ini-
tial severity of  disease might be a significant predictor of  
poor clinical outcome after steroid treatment[19,31,32]. Also, 
anemia is a common and important complication of  IBD 
with a prevalence rate ranging from 8.8% to 66.6% in UC 
patients[33,34]. The quality of  life, an ability of  work, and 
cognitive function can be impaired because of  anemia 
in IBD patients[35,36]. Impaired quality of  life by anemia 
in UC patients could influence patient well-being sense 
and PGA. For this reason, lower hemoglobin level could 
be a risk factor for poor response in our study. However, 
none of  the previous studies have evaluated duration of  
oral corticosteroid use before intravenous corticosteroids 
to predict outcome of  corticosteroid therapy in patients 
with UC. We found that the duration of  oral cortico-
steroid administration was an independent predictor of  
non-response to intravenous corticosteroid therapy on 
multivariate analysis in patients with acute exacerbation 
Table 3  Comparison of clinical factors in one month 
outcomes of the two groups of active ulcerative colitis 
patients receiving intravenous corticosteroids after oral 
corticosteroid therapy failure
Good responders1 
(n  = 44)
Poor responders2 
(n  = 12)
P -value 
univariate
Gender (M/F)       24/20 (54.5/45.5)           8/4 (66.7/33.3) 0.956
Age (yr)      37 (11-78)      38 (29-59) 0.342
Disease duration (mo)
   ≤ 24    25 (56.8)   9 (75) 0.253
   > 24    19 (43.2) 3 (3)
First attack of UC    18 (40.9)      8 (66.7) 0.113
Disease extent 0.943
   Proctitis    3 (6.8)    1 (8.3)
   Left-sided colitis    13 (29.5)      4 (33.3)
   Extensive colitis    28 (63.6)      7 (58.3)
Disease activity
   Full Mayo score 
(< 9/≥ 9)
      23/19 (54.8/45.2)           4/5 (44.4/55.6) 0.574
   Partial Mayo 
score (< 6/≥ 6)
      12/32 (27.3/72.7)         2/10 (16.7/83.3) 0.452
Initial prednisolone dose (mg) 0.429
   ≥ 30 and < 40    24 (54.5)      5 (41.7)
   ≥ 40    20 (45.5)      7 (58.3)
Duration of oral corticosteroid use (d)
   ≤ 14    26 (59.1)      7 (58.3) 0.962
   > 14    18 (40.9)      5 (41.7)
Concomitant medications 0.212
   Salicylates 33 (75)    11 (91.7)
   Azathioprine 11 (25)    1 (8.3)
CRP (mg/dL)
   ≤ 8    28 (63.6)   9 (75) 0.461
   > 8    16 (36.4)   3 (25)
ESR (mm/h)   40.7 (3-120)   37.2 (12-83) 0.464
Hemoglobin (mg/dL)
   ≤ 11    15 (34.1)   3 (25) 0.550
   > 11    29 (65.9)   9 (75)
Albumin (mg/dL)       3.6 (2.3-5.0)     3.45 (2.6-4.8) 0.295
1Good responders included patients with prolonged response that 
maintained complete remission or partial remission after completion of 
corticosteroid therapy; 2Poor responders included patients with steroid 
dependence and non-response. M/F: Male/female; UC: Ulcerative colitis; 
CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate. 
Table 4  Comparison of clinical factors in three month 
outcomes of the two groups of active ulcerative colitis 
patients receiving intravenous corticosteroids after oral 
corticosteroid therapy failure
Good responders1 
(n  = 37)
Poor responders2 
(n  = 18)
P -value 
univariate
Gender (M/F)       21/16 (56.8/43.2)       10/8 (55.6/44.4) 0.933
Age (yr)      35 (13-78)    41 (20-62) 0.146
Disease duration (mo)
   ≤ 24    22 (59.5)  12 (66.7) 0.606
   > 24    15 (40.5)    6 (33.3)
First attack of UC    15 (40.5)  10 (55.6) 0.294
Disease extent 0.317
   Proctitis    3 (8.1)  1 (5.6)
   Left-sided colitis      9 (24.3)    8 (44.4)
   Extensive colitis    25 (67.6) 9 (50)
Disease activity
   Full Mayo score 
(< 9/≥ 9)
      20/14 (58.8/41.2)         7/9 (43.8/56.3) 0.318
   Partial Mayo 
score (< 6/≥ 6)
      11/26 (29.7/70.3)       3/15 (16.7/83.3) 0.297
Initial prednisolone dose (mg) 0.925
   ≥ 30 and < 40    19 (51.4) 9 (50)
   ≥ 40    18 (48.6) 9 (50)
Duration of oral corticosteroid use (d) 0.639
   ≤ 14    23 (62.2)  10 (55.6)
   > 14    14 (37.8)    8 (44.4)
Concomitant medications 0.180
   Salicylates 27 (73)  16 (88.9)
   Azathioprine 10 (27)    2 (11.1)
CRP (mg/dL)
   ≤ 8    24 (64.9)  12 (66.7) 0.895
   > 8    13 (35.1)    6 (33.3)
ESR (mm/h)   36.9 (3-120) 47.6 (6-120) 0.251
Hemoglobin (mg/dL)
   ≤ 11    14 (37.8)    4 (22.2) 0.247
   > 11    23 (62.2)  14 (77.8)
Albumin (mg/dL)     3.73 (2.7-5.0)   3.44 (2.3-4.6) 0.082
1Good responders included patients with prolonged response that 
maintained complete remission or partial remission after completion of 
corticosteroid therapy; 2Poor responders included patients with steroid 
dependence and non-response. M/F: Male/female; UC: Ulcerative colitis; 
CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate. 
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of  UC. Patients with UC with more severe disease ac-
tivity achieved remission less often than who tended to 
achieve remission earlier[37]. The duration of  oral corti-
costeroid therapy was likely to reflect the severity nature 
of  UC in these non-responding patients. Additionally, 
prolonged oral corticosteroid therapy might be associ-
ated with mortality and morbidity such as infection and 
sepsis in UC patients undergoing surgery. With regard to 
the duration of  intravenous corticosteroid treatment, the 
limit of  7-10 d for certifying the criteria of  steroid resis-
tance was based on historical series, which showed that 
the median time of  remission of  UC was 7.5 d and that 
prolonged treatment beyond 10 d did not increase the re-
mission rate[37]. In contrast with this point of  view, a large 
retrospective study of  single experienced hospital was 
in favor of  more conservative approach, which entered 
into remission within the 21 d of  treatment[38]. Therefore 
it is difficult to define resistance to corticosteroid which 
day after treatment is used as a limit marker. None of  the 
previous studies have shown duration of  oral cortico-
steroid administration was an independent predictor of  
non-response to intravenous corticosteroid therapy. This 
result demonstrates that optimal timing of  intravenous 
corticosteroids after oral therapy was an important clini-
cal factor of  medical treatment response. In other words, 
use of  oral corticosteroids for more than two weeks ap-
pears to be less effective in terms of  clinical outcome. 
Additionally, long term oral corticosteroids use could lead 
to worse clinical outcomes and complications. An extend-
ed pre-operative use of  steroids might increase the risk 
of  surgical complications[39,40]. UC patients undergoing 
an elective surgery have been shown to be at an increased 
risk of  postoperative infectious complications in patients 
treated with corticosteroids[40]. In our study, a total of  9 
patients underwent elective proctocolectomy within 1 
year. Among of  them, one patient died of  pneumonia 
and sepsis after proctocolectomy. Therefore, in the man-
agement of  UC, the optimal timing of  administration 
of  intravenous corticosteroids after oral corticosteroid 
failure should be determined within two weeks after oral 
corticosteroid therapy. However, the optimal time limit 
with oral corticosteroid therapy in the face of  response 
has not been clearly defined by randomized controlled 
trials. Therefore, large scaled, prospective studies are 
needed to confirm this result.
Yoon et al[10] reported that partial Mayo score was a 
predictive factor of  steroid dependency in steroid-naïve 
patients with UC. In our study, we also showed that ini-
tial higher partial Mayo score might be associated with 
long term poor prognosis of  corticosteroid therapy. 
Considered overall, the partial Mayo scores could help to 
predict long term potential corticosteroid dependency or 
refractoriness in active UC patients who are treated with 
systemic corticosteroid therapy.
Our study on clinical outcomes and factors for re-
sponse prediction after intravenous therapy after oral 
corticosteroids failure in active UC patient has clear clini-
cal significance. There have been no previously published 
studies describing the clinical course of  patients with 
acute attack of  UC who were treated first with oral corti-
costeroids and subsequently intravenous corticosteroids. 
This study may provide valuable clinical data that can be 
used in the management of  UC patients receiving oral 
corticosteroids therapy. Such studies could also be used 
to suggest optimal timing for administration of  intrave-
nous corticosteroids in UC patients who are treated with 
oral corticosteroids. Moreover, our enrolled UC patients 
possessed the quality of  comparatively homogenous cor-
ticosteroid therapy indication and same dose of  cortico-
steroids. These facts might be advantageous in terms of  
eliminating confounding factors.
There were several limitations in our study. Our study 
was a retrospective study in a single tertiary hospital. Mu-
cosal healing has emerged as an important treatment goal 
in UC because evidence is accumulating that it can alter 
the clinical course of  UC. However, evidence of  cortico-
Table 5  Comparison of clinical factors in one year outcomes 
of the two groups of active ulcerative colitis patients receiving 
intravenous corticosteroids after oral corticosteroid therapy 
failure
Good responders1 
(n  = 25)
Poor responders2 
(n  = 29)
P -value 
univariate
Gender (M/F)  15/10 (60/40) 16/13 (55/45) 0.721
Age (yr)       35 (16-78)      39 (13-64) 0.445
Disease duration 
(mo)
    30 (0-84)      29 (0-120) 0.325
   ≤ 24  14 (56) 20 (69)
   > 24  11 (44)   9 (31)
First attack of UC    9 (36)    15 (51.7) 0.248
Disease extent 0.304
   Proctitis  1 (4)      3 (10.3)
   Left-sided colitis    6 (24)    11 (37.9)
   Extensive colitis  18 (72)    15 (51.7)
Disease activity
   Full Mayo score 
(< 9/≥ 9)
         15/9 (62.5/37.5) 11/14 (44/56) 0.195
   Partial Mayo 
score (< 6/≥ 6)
   9/16 (36/64)         4/25 (13.8/86.2) 0.057
Initial prednisolone dose (mg) 0.785
   ≥ 30 and < 40  13 (52)    14 (48.3)
   ≥ 40  12 (48)    15 (51.7)
Duration of oral corticosteroid use (d) 0.337
   ≤ 14  17 (68)    16 (55.2)
   > 14    8 (32)    13 (44.8)
Concomitant medications 0.771
   Salicylates  19 (76)    23 (79.3)
   Azathioprine    6 (24)      6 (20.7)
CRP (mg/dL)
   ≤ 8     16 (64%)    19 (65.5) 0.907
   > 8       9 (36%)    10 (34.5)
ESR (mm/h)  34.1 (4-81)   46.3 (3-120) 0.171
Hemoglobin (mg/dL)
   ≤ 11    9 (36)      8 (27.6) 0.507
   > 11  16 (64)    21 (72.4)
Albumin (mg/dL)        3.8 (2.7-4.7)     3.57 (2.3-5.0) 0.230
1Good responders included patients with prolonged response that 
maintained complete remission or partial remission after corticosteroid 
therapy had finished; 2Poor responders included patients with steroid 
dependence and non-response. M/F: Male/female; UC: Ulcerative colitis; 
CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate.
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steroid’s ability to promote mucosal healing is limited. A 
considerable portion of  a period in this study was at mo-
ment before mucosal healing has emerged as an emerging 
parameter in UC. Then we could not evaluate the mucosal 
healing as a parameter of  clinical outcomes in this study. 
Moreover, our study was not a placebo-controlled com-
parative study. Finally, the sample size was relatively small.
In conclusion, our study showed that most Korean 
patients with active UC responded well to intravenous 
corticosteroid therapy after oral corticosteroid therapy 
failure. However, a considerable number of  patients 
turned out to be refractory to or dependent on this 
therapy. The duration of  oral corticosteroid therapy and 
lower hemoglobin level were strongly associated with 
poor outcome. Further prospective studies are warranted 
to confirm these results and to determine the optimal 
timing and dose of  corticosteroids.
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